U.S. Meningococcal Vaccines Market Size & Outlook, 2026-2033

Name: U.S. Meningococcal Vaccines Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The meningococcal vaccines market in the United States is expected to reach a projected revenue of US$ 2,652.8 million by 2033. A compound annual growth rate of 3% is expected of the United States meningococcal vaccines market from 2026 to 2033.

U.S. meningococcal vaccines brand outlook (Revenue, USD million, 2021-2033)
- Menactra
- Menveo
- Nimenrix
- Trumenba
- Bexsero
- Others
U.S. meningococcal vaccines serotype outlook (Revenue, USD million, 2021-2033)
- A
- B
- C
- W-135
- Y
U.S. meningococcal vaccines age group outlook (Revenue, USD million, 2021-2033)
- Infants (0 to 2 years)
- Children and Adults (2 years and above)
U.S. meningococcal vaccines sales channel outlook (Revenue, USD million, 2021-2033)
- Private
- Public
U.S. meningococcal vaccines type outlook (Revenue, USD million, 2021-2033)
- Bivalent
- Quadrivalent
- Others

U.S. Meningococcal Vaccines Market Size & Outlook, 2026-2033

Sign up - it's easy, and free!